Alpa Laboratories growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
−5.9%+3.4%+17.6%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−30.8%−41.4%+7.3%
−53.0%−58.5%−1.3%
−23.0%+16.3%+32.8%
−28.2%+16.6%+35.8%
+8.8%+21.9%+9.1%
+8.7%+12.9%+12.9%
+41.0%+93.4%+175.3%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ALPA₹52.62

Alpa Laboratories Limited

· Pharma & Health
₹ CrorePeersBALPHARMAKREBSBIONATCAPSUQVINEETLABNECLIFEAAREYDRUGSBIOFILCHEMMANGALAMMcap ₹111 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+17.6+3.4-5.9—
EBITDA Growth—+7.3-41.4-30.8—
EBIT Growth—-1.3-58.5-53.0—
Net Income Growth—+32.8+16.3-23.0—
EPS Growth—+35.8+16.6-28.2—
Total Assets Growth—+9.1+21.9+8.8—
Total Equity Growth—+12.9+12.9+8.7—
Cash from Operations Growth—+175.3+93.4+41.0—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.